As part of its collaboration with Belgium-based biotech Galapagos (Euronext: GLPG), Servier has exercised its option to develop the osteoarthritis (OA) molecule GLPG1972/S201086.
This gives the privately-held French drugmaker global commercial rights to the molecule outside the USA.
Since June 2010, Servier and Galapagos have been seeking to find a treatment capable of counteracting disease progression in OA, leading to the development of what they believe could be a disease-modifying molecule.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze